LDC and Qurient sign licence agreement to advance CDK7 inhibitors for the treatment of cancer
3 June 2015 | By Victoria White
LDC and Qurient have signed a licence deal providing Qurient with exclusive worldwide rights to a series of highly-selective CDK7 inhibitors...